Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma

  title={Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1\% and Timolol Maleate 0.5\% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma},
  author={Shiro Mizoue and Koji Nitta and Motohiro Shirakashi and Akiyoshi Nitta and Shigeki Yamabayashi and Tairo Kimura and Toshihiko Ueda and Ryuji Takeda and Shun Matsumoto and Keiji Yoshikawa},
  journal={Advances in Therapy},
IntroductionThis study compared the efficacy and safety of adjunctive brimonidine tartrate 0.1% ophthalmic solution (brimonidine) and timolol maleate 0.5% ophthalmic solution (timolol) in prostaglandin analogue (PGA)-treated normal-tension glaucoma (NTG), assessing the non-inferiority of brimonidine in terms of intraocular pressure (IOP) reduction.MethodsIn this multicenter, randomized, investigator-masked, parallel-group, clinical study, adjunctive brimonidine or timolol was administered twice… Expand
Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
The IOP-lowering efficacy of Brim was non-inferior to that of Tim after stratification by baseline IOP (12 ≤ IOP ≤ 16 mmHg), and PR should be considered when selecting β-blockers for glaucoma treatment. Expand
The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15
In patients with POAG with an intraocular pressure of at most 15 mmHg undergoing FP monotherapy, the addition of ripasudil resulted in significant IOP lowering at 1 and 3 months, and could be used to enhance the outcome ofFP monotherapy. Expand
A review of neuropsychiatric adverse events from topical ophthalmic brimonidine
  • N. Cimolai
  • Medicine
  • Human & experimental toxicology
  • 2020
Topical ophthalmic brimonidine use should be followed for the occurrence of neuropsychiatric disturbances generally, and enhanced vigilance should be maintained for at-risk populations. Expand
Management of the glaucoma patient progressing at low normal intraocular pressure.
The most effective way of slowing the progression of glaucoma in a patient with low IOP is to lower the IOP further, sometimes to single digit levels, which is most often achievable with trabeculectomy. Expand


The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients
The addition of newly formulated brimonidine to on-treatment Japanese NTG patients with IOP of 13–16 mmHg further reduced the levels of IOP with minimal side effects and adverse events. Expand
A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treating with timolol 0.5%, and similar differences in progression were observed when analyzed by GCPM and the 3-omitting method. Expand
Effects of Switching from Timolol to Brimonidine in Prostaglandin Analog and Timolol Combination Therapy.
The main outcome measure was the change in intraocular pressure (IOP), and for safety evaluations, hyperemia, formation of conjunctival follicles, superficial punctate keratopathy as a local side effect, blood pressure (BP), and heart rate (HR) were evaluated. Expand
24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
This study suggests that brimonidine purite and dorzolamide, added to latanoprost, have similar efficacy and safety in POAG or ocular hypertensive subjects. Expand
Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Latanoprost seemed to lead to a fairly uniform circadian reduction in IOP, whereas timolol seemed to be less effective during the nighttime hours, whereas dorzolamide led to a significant reduction in nocturnal IOP. Expand
Systematic Review of Intraocular Pressure-Lowering Effects of Adjunctive Medications Added to Latanoprost
The addition of brimonidine, dorZolamide, timolol, or brinzolamide can further lower IOP in eyes being treated with latanoprost, and Timolol 0.5% once daily might be the most effective adjunctive medication. Expand
Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
Bimatoprost effectively lowered the intraocular pressure in Japanese normal-tension glaucoma patients and was well tolerated in Japanese NTG patients, with few patients having to discontinue because of adverse events. Expand
Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
This multi-center collaborative study suggests that IOP-lowering efficacy of travoprost ophthalmic solution persists during the day at the clinically relevant level in subjects with NTG. Expand
In vitro and in vivo corneal effects of latanoprost combined with brimonidine, timolol, dorzolamide, or brinzolamide.
When combining latanoprost containing benzalkonium chloride with other classes of antiglaucoma drugs, brimonidine may cause the least corneal damage, and the number of drug administrations may be an important factor. Expand
Meta-analysis of medical intervention for normal tension glaucoma.
Latanoprost, bimatop Frost, and timolol are the most effective IOP-lowering agents in patients with NTG. Expand